NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical logo
$6.38 -0.03 (-0.39%)
As of 03:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Advanced

Key Stats

Today's Range
$6.35
▼
$6.40
50-Day Range
$4.09
▼
$6.59
52-Week Range
$3.63
▼
$8.98
Volume
245,471 shs
Average Volume
283,489 shs
Market Capitalization
$241.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Reduce

Company Overview

Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products. The company works with customers on product development, formulation, analytical testing, regulatory support and commercial-scale manufacturing, including fill-finish services.

Lifecore also develops and manufactures hyaluronic acid, a biopolymer used in medical products and other applications. Its capabilities support products in areas such as ophthalmology and orthopedics, as well as pharmaceutical and veterinary uses.

Based in Chaska, Minnesota, Lifecore serves pharmaceutical and medical technology companies in the United States and internationally. The business has a history in hyaluronic acid production and has expanded its role as a CDMO serving customers from development through commercial manufacturing.

AI Generated. May Contain Errors.

Lifecore Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
22nd Percentile Overall Score

LFCR MarketRank™: 
1.09119411123 of 5 stars

Lifecore Biomedical scored higher than 22% of companies evaluated by MarketBeat, and ranked 1531st out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lifecore Biomedical has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.

  • Upside/Downside

    The consensus price target for Lifecore Biomedical is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Lifecore Biomedical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Lifecore Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($1.83) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lifecore Biomedical is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lifecore Biomedical is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    6.75% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently decreased by 4.49%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lifecore Biomedical does not currently pay a dividend.

  • Dividend Growth

    Lifecore Biomedical does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lifecore Biomedical this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.68% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lifecore Biomedical's insider trading history.
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LFCR Stock News Headlines

Lifecore Biomedical Inc.
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

LFCR Stock Analysis - Frequently Asked Questions

Lifecore Biomedical's stock was trading at $8.18 at the beginning of 2026. Since then, LFCR stock has decreased by 22.2% and is now trading at $6.3650.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) released its earnings results on Wednesday, November, 4th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.78. The business had revenue of $25.32 million for the quarter, compared to analyst estimates of $25.57 million.

Lifecore Biomedical's top institutional investors include State Street Corp (1.68%), Marshall Wace LLP (0.68%), Allspring Global Investments Holdings LLC (0.44%) and Tocqueville Asset Management L.P. (0.25%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs.
View institutional ownership trends
.

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/04/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:LFCR
CIK
1005286
Employees
382
Year Founded
1965

Price Target and Rating

High Price Target
$6.50
Low Price Target
$6.50
Potential Upside/Downside
+2.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
-56.80%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-29.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.84
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$128.87 million
Price / Sales
1.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.94) per share
Price / Book
-3.29

Miscellaneous

Outstanding Shares
37,906,000
Free Float
25,518,000
Market Cap
$241.65 million
Optionable
Optionable
Beta
0.99

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:LFCR) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners